, ·	
Please type a plus sign (+) inside this box ->	+

TON & TRAD

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known tute for form 1449B/PTO Application Number 09/214,881 INFORMATION DISCLOSURE June 7, 1999 Filing Date First Named Inventor Ozaki et al. STATEMENT BY APPLICANT 1644 Group Art Unit (use as many sheets as necessary) **Examiner Name** P. Nolan 068383.0104 Attorney Docket Number of

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issued number(s), publisher, city and/or country where published.	T²
PN	AA	CLAYTON et al, "Measurement of antibody to poly (adenosine diphosphate-ribose): its diagnostic value in systemic lupus erythematosus," 1984, pp. 263-271, Clin. exp. Immunol.	
PN	AB	YUNG, et al, "Sex-Specific Differences in T Cell Homing May Explain Increased Disease Severity in Female Mice," July 1997, pp. 1334-1343, Vol. 40 No. 7, Arthritis & Rheumatism	
PN	AC	NEUER et al., "Autoantibodies to the Chromosomal Protein HMG-17 in Juvenile Rheumatoid Arthritis," April 1992, pp. 472-475, Vol. 35 No. 4, Arthritis & Rheumatism	
**			
	-,,-		

Examiner	D - C 110	Dated	1/20/02/
Signature	fath of ML	Considered	6129104

HOU03:734562.1*

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{**}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

OIPE				Pa	nge I of I
DEE 0 4 2	Forth PTO-1449 (modified)		Atty. Docket No. 13240.0004.NPUS00	Serial No. 09/214,881	,`\
List of Patents and Publications for Applica INFORMATION DISCLOSURE STATEME			Ozaki et al.		of Chil
	(Use several sheets if necessa	ry)	Filing Date: June 7, 1999	Group: 1644	Tip do
	U.S. Patent Documents N/a	Foreign	Patent Documents N/A	Other Art See Page 1	0000

Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	Cl	European Examination Report; August 28, 2003
PN	C2	"Anti-Neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis; anti-cathepsin G and a novel antibody correlate with a refractory type;" J. Sobajima, S. Ozaki, T. Okazaki, F. Osakada, S. Sumita, K. Mori & K. Nakao; 1996 Blackwell Science Ltd, Clinical and Experimental Immunology; pp. 120-124
PN	C3	"Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis;" Wolfgang L. Gross, Elena Csernok and Udo Helmchen; 1995 APMIS 103, pp. 81-97
	C4	
	C5	
	C6	
	C7	
	C8	
	С9	
	C10	
	CII	
	C12	
	C13	
	C14	
	C15	
	C16	
	C17	
	C18	
	C19	
•	C20	

Examiner: fatur IND Com	DATE CONSIDERED:	6/29/04	

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.